고지질혈증의 약물치료 Pharmacologic therapy of hyperlipidemia

목차

1. Lipid metabolism
2. Frederickson Classification of Hyperlipoproteinemia
3. Target LDL-C Level
4. Therapeutic goal
5. Pharmacologic treatment
6. HMG-CoA Reductase Inhibitors
7. Cholesterol Absorption Inhibitors
8. Bile Acid Sequestrants
9. Nicotinic Acid
10. Fibric acid Derives
11. Omega 3 Fatty Acids
12. Combination drug therapy
13. Reference

본문내용

Therapeutic goal
Lower LDL level as possible in target range!

Changing Face of Dyslipidemia Therapy, Amal Kumar Banerjee, Institute of Cardiovascular Sciences,2008
HDL inhibit platetlet activation and aggregation
HDL cholesterol level was more potent as a risk factor for CHD than was the level of LDL cholesterol
combination therapy with atorvastatin and ER niacin causes significantly rise in HDL levels, greater lowering of total cholesterol and LDL cholesterol when compared to atorvastatin monotherapy

Pharmacologic treatment
HMG-CoA Reductase Inhibitors(Statins)
Cholesterol Absorption Inhibitors
Bile Acid Sequestrants(Resins)
Nicotinic Acid(Niacin)
Fibric acid Derives(Fibrates)
Omega 3 Fatty Acids(Fish Oils)

참고 자료

David Preiss, Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence, Clinical Endocrinology, 2008, .1365-2265.2008
Teng-Yeow Tan, et al., Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis, J Neurol (2009) 256:187–193
Amal Kumar Banerjee, Changing Face of Dyslipidemia Therapy, Institute of Cardiovascular Sciences
André J Tremblay, et al., Effects of Ezetimibe and Simvastatin, coadministered and alone, on the in vivo kinetics op APOB-48 and APOB-100 in men with mixed hyperlipidemia, J of lipid research
Kwang Kon Koh. Et al., Vascular and metabolic effects of treatment of combined hyperlipidemia: Focus on statins and fibrates, International Journal of Cardiology 124 (2008) 149–159
Tenenbaum A. et al., Optimal management of combined dyslipidemia: what have we behind statins monotherapy?, Adv cardiol.